Those looking into stocks that have clocked meaningful gains over the course of the past month have plenty of options to look into and one of those is the Emmaus Life Sciences Inc (OTCMKTS:EMMA) stock.
The biopharmaceutical firm, which is at a commercial stage, has seen its stock soar by as much as 7% over the course of the past month. While it is true that there has not been any news about the company in recent days, it might be a good idea for investors to take a look at a development from earlier on this month on September 2.
On that day, the company announced its financial results for the half year period that ended on June 30, 2021. More importantly, the announcement made Emmaus current with regards to its reporting responsibilities with the United States Securities and Exchange Commission.
The net revenues for the period came in at $11.8 million, which worked out to a year on year rise of 5%. The revenues went up in the particular period because of the rise in value of bulk order purchases. In addition to that, that company had also managed to make a recovery from the disruptions caused to its sales processes by the COVID 19 pandemic.
